{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012322","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.125854+00:00","generated_at":"2026-06-24T22:25:38.563054+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Inhibikase Therapeutics 2022 Annual Meeting results: share count increase fails","bullets":["Directors Roy Freeman and Paul Grint elected with ~11.4M and ~11.5M votes for; ~4.5M broker non-votes.","Ratification of CohnReznick LLP as auditor approved: 16.4M for, 31.5K against, 56.6K abstain.","Proposal to increase authorized shares from 100M to 200M failed: 15M for, 1.4M against, not meeting required percentage."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012322","json":"https://secwatch.observer/filing/0000950170-22-012322.json","markdown":"https://secwatch.observer/filing/0000950170-22-012322.md","text":"https://secwatch.observer/filing/0000950170-22-012322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/0000950170-22-012322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/ikt-20220624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:25:38.563054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}